Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Hypercholesterolemia treatment is one of the main approach in primary and secondary prevention of atherosclerotic cardiovascular diseases (CVD). LDL-cholesterol reduction about 1 mmol/L reduces ischemic cardiovascular events about 25%.
The CVD mortality reduction more than 50% represents a big success of the Czech health care during the last 25 years. Appart from that success, statin therapy is still used insufficiently.
Less attention is also done to non-LDL dyslipidemia, e.g. atherogenic dyslipidemia (increased triglycerides and/or reduced HDL-cholesterol), which is considered as residual lipid risk for CVD especially in diabetic and prediabetic patients.